NTRK1 and neoplasm: More recently, an integrated interim analysis of three phase I–II clinical trials (ALKA-372–001, STARTRK-1 and STARTRK-2), evaluating the anti-tumour activity and safety of entrectinib (another tropomyosin receptor kinase inhibitor) for patients with TRK-fusion-positive solid tumours, showed an ORR of 57% (7% complete response and 50% partial response) with a median DOR of 10 months.